Skip to main content
letter
. 2023 May 31;13(1):91. doi: 10.1038/s41408-023-00859-x

Fig. 1. Response and survival.

Fig. 1

a Clinical, hematological, PET, and VEGF responses in POEMS patients treated with daratumumab-based therapies and carfilzomib-based therapies. b Time to next treatment.